CDEK
← All drugs Report issue

delamanid

Small moleculeexperimental

Delamanid is sold under the brand name Deltyba, is a medication used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. It is taken by mouth. — Wikipedia

Clinical trial activity

38 trials · 80 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
31
Phase 3
10
Phase 4
3

Earliest trial started Mar 1, 2003 (NCT00042289)

Timeline

2000s

  1. Jan 1, 2006

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2013

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

  • Mycobacterium tuberculosis H37RvINHIBITOR

    Mycobacterium tuberculosis H37Rv inhibitor

    Inhibits the synthesis of mycobacterial cell wall components, methoxy mycolic acid and ketomycolic acid. Pro-drug activated by the enzyme deazaflavin dependent nitroreductase

Chemistry & pharmacology

Loading structure…

SMILES

C[C@]1(COc2ccc(N3CCC(Oc4ccc(OC(F)(F)F)cc4)CC3)cc2)Cn2cc([N+](=O)[O-])nc2O1
Mol. weight
534.49 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Prodrug

Sources

Also known as

  • delamanid
  • delamanid
  • delamanid
  • delamanid
  • delamanid
  • delamanid
  • delamanid
  • deltyba
  • deltyba
  • deltyba
  • deltyba
  • opc-67683
  • opc-67683
  • opc-67683
  • opc-67683
  • opc-67683

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07198685N/ASep 30, 2025Huazhong University of Science and Technology
NCT07170800Phase 2Sep 10, 2025Government of China
NCT07126639N/ASep 1, 2025Huazhong University of Science and Technology
NCT07129629Phase 2Aug 20, 2025Fudan University, Huazhong University of Science and Technology
NCT06649721Phase 3Nov 15, 2024Capital Medical University, Fudan University
NCT06114628Phase 2Dec 8, 2023German Center for Infection Research, GlaxoSmithKline, Government of France, Janssen Pharmaceutica NV, KNCV Tuberculosis Foundation, Otsuka, Radboud University, Research Center Borstel, TASK Applied Science, TB Alliance, Tuberculosis Network European Trialsgroup, University of California, San Francisco, University of Cambridge, University of Hamburg, University of Liverpool, University of London, University of Milan, University of Oxford, University of Porto, University of St Andrews, Uppsala University, Vita-Salute University of Milano. Italy
NCT06081361Phase 3Nov 1, 2023Capital Medical University
NCT06224036Phase 2Oct 31, 2023Capital Medical University, Huazhong University of Science and Technology, Sichuan University
NCT05926466Phase 2Sep 21, 2023Ludwig Maximilians University, Radboud University, University of California, San Francisco, University of London
NCT05971602Phase 2Jul 26, 2023Bill and Melinda Gates Foundation, Global Alliance for TB Drug Development, Janssen Pharmaceutica NV, Otsuka
NCT05807399Phase 2Apr 14, 2023GlaxoSmithKline, LegoChem Biosciences, Inc, Ludwig Maximilians University, Radboud University, University of California, San Francisco, University of London
NCT05556746Phase 2Mar 31, 2023Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic, Harvard University, Stellenbosch University, University of California, Los Angeles, University of Cape Town
NCT05766267Phase 2/Phase 3 (Phase 3)Mar 1, 2023Centers for Disease Control and Prevention (CDC), Cornell University, Johns Hopkins University
NCT05382312Phase 2Jul 26, 2022Click-TB Consortium, GlaxoSmithKline
NCT05221502Phase 2Apr 12, 2022Bill and Melinda Gates Foundation, Otsuka
NCT04550832Phase 2Oct 22, 2021LegoChem Biosciences, Inc, Ludwig Maximilians University, Radboud University, University of California, San Francisco
NCT05007821Phase 2Sep 13, 2021National Institute of Allergy and Infectious Diseases (NIAID)
NCT05278988Phase 4Apr 1, 2021Anhui Medical University, Fudan University, Huazhong University of Science and Technology, Jiao Tong University, Weifang People's Hospital, Zhengzhou University
NCT04421495Phase 4Jul 31, 2020Capital Medical University
NCT03828201Phase 3Jan 31, 2020Boston University, Harvard University, National Institute of Allergy and Infectious Diseases (NIAID), Novartis, Otsuka, Pfizer, University of California, San Francisco, University of Colorado, Denver, Westat
Showing 20 of 38 trials
Page 1 / 2

Organizations

Research & Development (80)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
OtsukaFor profit13932006
University of California, San FranciscoAcademic/Hospital7022019
National Institute of Allergy and Infectious Diseases (NIAID)Government6532003
Huazhong University of Science and TechnologyAcademic/Hospital5432021
Radboud UniversityAcademic/Hospital5012019
University of Cape TownAcademic/Hospital5022006
Capital Medical UniversityAcademic/Hospital4332020
Harvard UniversityAcademic/Hospital4122016
Johns Hopkins UniversityAcademic/Hospital4022016
Ludwig Maximilians UniversityAcademic/Hospital4312019
Bill and Melinda Gates FoundationAcademic/Hospital3112018
Boston UniversityAcademic/Hospital3222003
Fudan UniversityAcademic/Hospital3132021
GlaxoSmithKlineFor profit3112022
Stellenbosch UniversityAcademic/Hospital3022018
University of LondonAcademic/Hospital3112023
EpicentreFor profit2012016
Institute of Tropical Medicine, BelgiumAcademic/Hospital2012016
Janssen Pharmaceutica NVFor profit2012023
LegoChem Biosciences, IncFor profit2112021
80 organizations
Page 1 / 4